Entecavir 0.5 mg tablets recalled for out of specification organic impurity
Zydus is recalling 912 bottles of Entecavir Tablets USP 0.5 mg from one lot after an individual organic impurity returned an out-of-specification result.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Scored 2 as a specification failure: the record identifies an out-of-specification impurity result without naming the impurity, describing a health consequence, or reporting any injury.
Plain-English summary
Entecavir Tablets, USP, 0.5 mg, in 30-count bottles, manufactured by Zydus Lifesciences Ltd. of Ahmedabad, India and distributed by Zydus Pharmaceuticals (USA) Inc. of Pennington, New Jersey, are being recalled for failed impurity and degradation specifications, specifically an out-of-specification result for an individual organic impurity.
The recall covers 912 bottles from lot E409308 with an expiration date of 31 December 2026, carrying NDC 68382-920-06. The product was distributed nationwide in the United States. The FDA has classified the recall as Class II.
The enforcement record does not name the impurity or state a health consequence, and reports no injuries. Entecavir is a prescription antiviral, so patients holding the affected lot should contact their pharmacy or prescriber about a replacement rather than stopping treatment on their own.
The recalled product
- Product
- ENTECAVIR (ENTECAVIR)
- Brand
- ENTECAVIR
- Manufacturer
- Zydus Pharmaceuticals (USA) Inc
- Category
- Drug — Antiviral
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: E409308
- Exp 12/31/2026
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Zydus Pharmaceuticals (USA) Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · ENTECAVIR
- ModerateEntecavir 1 mg tablets recalled for out of specification organic impurity
FDA (Drugs) · 2025-10-08
- HighEntecavir 1 mg tablets recalled after failing impurity and degradation specifications
FDA (Drugs) · 2025-09-24
- HighEntecavir tablets recalled after failing impurity and degradation specifications
FDA (Drugs) · 2025-09-24
- ModerateHetero USA Recalls Entecavir Tablets Due to Impurity Specification Failure
FDA (Drugs) · 2017-08-23
Same manufacturer · Zydus Pharmaceuticals (USA) Inc
See all →- SevereFDA Recalls Mirabegron Tablets Over Nitrosamine Impurity
FDA (Drugs) · 2026-08-12
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereErythromycin 500 mg Tablets Recalled for Impurity Above Limits
FDA (Drugs) · 2026-05-27
- HighIcosapent ethyl capsules recalled after active ingredient oxidized inside capsule
FDA (Drugs) · 2026-03-18
- HighIcosapent ethyl capsules recalled as subpotent after capsule contents leaked
FDA (Drugs) · 2026-01-28
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17